Nordic Nanovector has announced the appointment of Peter L. Braun as Chief Executive Officer (CEO).
He took up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland.
Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialization experience with innovative oncology products and deep knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche, states the company in a press release.
Various operational leadership positions
Braun has also held various operational leadership positions including being country general manager and multiple commercial roles in Europe, US and Latin America. He has developed expertise across multiple strategic and operational roles including development, manufacturing, business development and market access for innovative therapeutic products in several geographies and other therapeutic areas, including rare diseases and infectious diseases.
In addition to his experience at Roche, Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies.
“I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that targeted cancer therapeutics represent an important treatment modality and well tolerated, targeted radiopharmaceuticals, such as Betalutin, can make a real difference to patients. I look forward to working closely with the Board and the leadership team to bring this innovative drug to NHL patients worldwide,” says Braun.